Letters to the Editor must not exceed 400 words in length and must be limited to three authors and five references. They should not have tables or figures and should relate solely to an article published in Circulation within the preceding 12 weeks. Authors of letters selected for publication will receive prepublication proofs, and authors of the article cited in the letter will be invited to reply. Replies must be signed by all authors listed in the original publication. Please submit three typewritten, double-spaced copies of the letter to Herbert L. Fred, MD, % the Circulation Editorial Office. Letters will not be returned.

Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib

To the Editor:

As editors of a journal devoted to the promotion of evidence-based medicine, we search for and abstract the most relevant (valid and clinically important) reports originally published in the top English language medical journals. For the last few years, we have been following reports regarding the clinical use, efficacy, and potential side effects of selective COX-2 inhibitors. On the basis of inappropriate methodology, we have recently rejected the publication by Mukherjee et al from our abstracts. In the recent report, Konstam et al provided data on the relative rate of cardiovascular events in controlled trials of rofecoxib. To better appraise the validity of their conclusion, we wish to ask the authors for information on 3 aspects of their analysis.

What are the results of an intent-to-treat analysis in which all patients randomized to a given treatment were analyzed? The analysis, as reported by the authors, was a “modified intention-to-treat approach” in which patients were included only if they received at least 1 dose of the study drug. We do not consider those 2 analyses equivalent.

If results of intent-to-treat analysis are not available, 2 further issues gain importance. First, what was the proportion of patients removed from analysis after randomization because they did not take any dose of the drug? Second, were patients and caregivers blinded to treatment allocation in all trials (the authors state that outcome-assessors were blinded)? If not, what are the results of analysis looking at the group of blinded trials?

Finally, if one were to allow the use of aspirin in all trials, the expected result would be the lack of difference in cardiovascular events (vide CLASS trial). From Table 1, it appears that in trials involving almost 10,000 patients, use of aspirin was actually allowed. What are the results of analysis looking only at the trials in which use of aspirin was not allowed?

We would greatly appreciate help in resolving these questions.

Roman Jaeschke, MD, PhD
McMaster University
Hamilton, Canada

Piotr Gajewski, MD, PhD
Jan Brozek, MD
Department of Medicine
Jagiellonian University
Krakow, Poland

Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Roman Jaeschke, Piotr Gajewski and Jan Brozek

Circulation. 2002;106:e18
doi: 10.1161/01.CIR.0000023454.92028.12
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2002 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/106/5/e18

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/